1993 Fiscal Year Final Research Report Summary
Development of Slow Releasing Anticancer Drug Based with Absorbable Biomaterial Chit*
| Project/Area Number |
04807093
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Shimane Medical University |
|---|
Principal Investigator |
MATSUURA Hiroshi Shimane Medical University, Assistant Professor, 医学部, 講師 (80157247)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAKAMURA Teruhisa Shimane Medical University, Professor, 医学部, 教授 (10038656)
KUBOTA Hirofumi Shimane Medical University, Assistant Professor, 医学部, 助手 (00205147)
|
|---|
| Project Period (FY) |
1992 – 1993
|
| Keywords | CDDP / Chitin / Plachitin / Slow releasing anticancer drug / topical application / chemoembolization / VX2 tumor |
|---|
| Research Abstract |
We studied the slow releasing property and anticancer, effect of Plachitin, which is reconstituted by combination of CDDP and chitin. This study deals in more detail with the slow releasing property, and the renal complications and the effectiveness for solid tumor were examined in mice and rabbits.
1. After implantation of Plachitin (cotton type) in the abdominal wall of mice, the platinum concentration in the different organs was measured. In the abudominal muscle around the implanted Plachitin, a high concentration of platinum was maintained until 8 weeks and the the peak was 4 weeks after implantation. At the same time, the serum concentration of platinum remained low. In the kidney, the platinum concentration resembled the levels in the abdominal muscle, but no renal dysfunction was found serologically or historogically.
2. When Plachitin was implanted around the solid tumor, the survival rates were improved and the gain in tumor weight was suppressed as compared with the controls.
… More
From these findings, Plachitin seemed to be effective as a slow releasing anticancer drug for topical application.
3. We studied about intraarterial chemoembolization therapy by use of Plachitin too. One gram of Plachitin contained 300mg CDDP and the form of Plachitin was modified into particles (about 50um in diameter). VX2 tumor was inoculated in hind limb of rabbits. When VX2 tumor was grown 2cm in diameter, Plachitin was injected in the femoral artery. The study was carried out in four groups : Plachitin, CDDP, chitin, and control groups. The tumor growth ratio was significantly lower in Plachitin group compared with other groups (p<0.05). Tumor regression was noticed in Plachitin group only. The tumor Platinum (Pt) level was higher than serum and kidney Pt.level. Blood urea nitrogen and Ceratinine level were normal range in Plachitin group. From the above results it can be concluded that Plachitin particles released CDDP slowly around the tumor and the tumor growth was suppressed by the additive effect of CDDP and embolization. Renal toxicity of Plachitin was not recognized. Plachitin could be considered as an useful agent for chemoembolization therapy for the cancer patients. Less
|
Research Products
(6 results)
